鼻腔疫苗市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疫苗類型、應用（流感、COVID-19、其他）、地區、競爭細分，2020-2030F

2024 年全球鼻腔疫苗市場價值為 4.252 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 6.05%。全球醫療保健格局不斷發展，近年來一個重大發展是鼻腔疫苗的出現。鼻腔疫苗為預防各種傳染病提供了一種新穎有效的方法，為傳統注射疫苗提供了一種非侵入性替代方案。隨著疫苗技術的進步和人們對其益處的認知不斷提高，全球鼻腔疫苗市場發展勢頭強勁。近年來，受多種關鍵因素推動，全球鼻腔疫苗市場實現了大幅成長。其中包括對無痛、便捷的疫苗接種方法的需求不斷成長、對預防性醫療保健的日益關注以及創新鼻腔疫苗製劑的開發。鼻腔疫苗對於兒童和害怕針頭的人來說特別有吸引力，使其成為免疫接種的首選。市面上經鼻給藥的疫苗種類不斷擴大。最初，鼻噴疫苗主要與流感疫苗有關，但現在涵蓋的疾病範圍更廣，包括新冠肺炎、麻疹、腮腺炎、德國麻疹等。這種多樣化極大地促進了市場的發展。製藥公司和研究機構正積極投入研發，以開發更有效、更強效的鼻腔疫苗製劑。這包括增強鼻腔疫苗的穩定性和傳遞機制。

各國政府和國際組織越來越認知到鼻噴疫苗在提高疫苗接種覆蓋率方面的潛力。這導致了對鼻噴疫苗研究和疫苗接種活動的投資增加，特別是在低收入和中等收入國家。公眾意識運動和教育工作在提高鼻腔疫苗接受度方面發揮著至關重要的作用。這些活動強調了鼻腔疫苗的優點，例如減輕疼痛、更容易接種和更快地形成免疫力。

肯塔基州市場促進因素

傳染病和呼吸道疾病發生率不斷上升

傳染病和呼吸道疾病發生率的上升是推動全球鼻腔疫苗市場擴張的主要驅動力。隨著全球流感、新冠肺炎、結核病 (TB) 和呼吸道合胞病毒 (RSV) 等疾病負擔不斷加劇，對有效、可及和非侵入性疫苗接種解決方案的需求日益增加。由於季節性流感和結核病的廣泛流行，全球醫療保健產業面臨重大挑戰。每年，季節性流感影響全球約 10 億人，其中 300 萬至 500 萬人會發展為重症。該疾病每年導致約 29 萬至 65 萬人死於呼吸系統疾病，對醫療保健系統和經濟生產力造成巨大壓力。

同樣，結核病（TB）仍然是全球面臨的重大健康挑戰。光是 2023 年，全球就有約 1,080 萬人感染結核病，其中影響 600 萬名男性、360 萬名女性和 130 萬名兒童。該疾病持續影響所有國家和年齡群體，加劇了其廣泛的公共衛生負擔。儘管結核病可以治癒和預防，但由於早期發現、治療機會和醫療保健基礎設施方面的差距，結核病仍然存在。鼻腔疫苗可提供有針對性的免疫反應，特別是針對空氣傳播的病原體，使其成為傳統注射疫苗的極具吸引力的替代品。呼吸系統疾病是全世界發病和死亡的主要原因之一。僅流感每年影響數百萬人，導致住院、經濟壓力和生產力損失。同樣，像 COVID-19 這樣的新興傳染病也強化了對可擴展且易於部署的疫苗接種策略的需求。 2020 年，慢性阻塞性肺病 (COPD) 影響了全球約 10.6% 的人口，男性和女性共有 4.8 億例。這種慢性呼吸系統疾病將繼續擴大，成為主要的公共衛生問題，預計到 2050 年病例將增加 23.3%。到那時，慢性阻塞性肺病病例總數預計將達到 5.92 億，佔全球高風險人口的 9.5%。鼻腔疫苗在預防呼吸系統疾病方面特別有效，因為它們模仿了空氣傳播病毒和細菌的自然感染途徑。感染率高的國家正在加大對預防免疫策略的投資，加速鼻腔疫苗技術的採用。

主要市場挑戰

監管障礙

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：鼻腔疫苗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疫苗類型（減毒活疫苗、不活化疫苗、次單位疫苗、重組疫苗及結合疫苗、其他）
  • 依用途分類（流感、新冠肺炎、其他（如霍亂、傷寒等））
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美鼻腔疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲鼻腔疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區鼻腔疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲鼻腔疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲鼻腔疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球鼻腔疫苗市場：SWOT 分析

第 14 章：競爭格局

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

第 15 章：策略建議

第16章調查會社について,免責事項

Global Nasal Vaccines Market was valued at USD 425.20 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.05% through 2030. The global healthcare landscape is continually evolving, and one significant development in recent years is the emergence of nasal vaccines. Nasal vaccines offer a novel and effective way to protect against various infectious diseases, providing a non-invasive alternative to traditional injection-based vaccines. The global nasal vaccines market has been gaining momentum, with advancements in vaccine technology and increasing awareness of their benefits. The global nasal vaccines market has witnessed substantial growth in recent years, driven by several key factors. These include a rising demand for painless and convenient vaccination methods, increased focus on preventive healthcare, and the development of innovative nasal vaccine formulations. Nasal vaccines are particularly appealing for children and individuals who fear needles, making them a preferred choice for immunization. The market has seen the expansion of the types of vaccines delivered nasally. Initially, nasal vaccines were primarily associated with influenza vaccines, but now they cover a wider range of diseases, including COVID-19, measles, mumps, rubella, and more. This diversification has significantly boosted the market. Pharmaceutical companies and research institutions are actively investing in R&D to develop more effective and potent nasal vaccine formulations. This includes enhancing the stability and delivery mechanisms of nasal vaccines.

Governments and international organizations are increasingly recognizing the potential of nasal vaccines in improving vaccination coverage rates. This has led to greater investments in research and vaccination campaigns using nasal vaccines, particularly in low-income and middle-income countries. Public awareness campaigns and educational efforts are playing a vital role in increasing the acceptance of nasal vaccines. These campaigns highlight the advantages of nasal vaccines, such as reduced pain, easier administration, and quicker immunity development.

Ky Market Drivers

Growing Prevalence of Infectious and Respiratory Diseases

The rising incidence of infectious and respiratory diseases is a key driver fueling the expansion of the global nasal vaccines market. As the global burden of diseases such as influenza, COVID-19, tuberculosis (TB), and respiratory syncytial virus (RSV) continues to escalate, there is an increasing demand for effective, accessible, and non-invasive vaccination solutions. The global healthcare sector faces significant challenges due to the widespread prevalence of seasonal influenza and tuberculosis (TB). Each year, seasonal influenza affects approximately one billion people worldwide, with 3 to 5 million cases progressing to severe illness. The disease is responsible for an estimated 290,000 to 650,000 respiratory-related deaths annually, creating substantial strain on healthcare systems and economic productivity.

Similarly, tuberculosis (TB) remains a critical global health challenge. In 2023 alone, an estimated 10.8 million people contracted TB worldwide, affecting 6.0 million men, 3.6 million women, and 1.3 million children. The disease continues to impact all countries and age groups, reinforcing its widespread public health burden. Despite being both curable and preventable, TB persists due to gaps in early detection, treatment access, and healthcare infrastructure. Nasal vaccines provide a targeted immune response, particularly against airborne pathogens, making them a highly attractive alternative to traditional injectable vaccines. Respiratory diseases are among the leading causes of morbidity and mortality worldwide. Influenza alone affects millions annually, leading to hospitalizations, economic strain, and loss of productivity. Similarly, emerging infectious diseases like COVID-19 have reinforced the need for scalable and easily deployable vaccination strategies. In 2020, chronic obstructive pulmonary disease (COPD) affected an estimated 10.6% of the global population, translating to 480 million cases across both men and women. This chronic respiratory condition continues to expand as a major public health concern, with projections indicating a 23.3% increase in cases by 2050. By that time, the total number of COPD cases is expected to reach 592 million, representing 9.5% of the global at-risk population. Nasal vaccines are particularly effective in preventing respiratory diseases because they mimic the natural infection route of airborne viruses and bacteria. Countries with high infection rates are increasingly investing in preventive immunization strategies, thereby accelerating the adoption of nasal vaccine technologies.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the nasal vaccines market is navigating the complex regulatory landscape. The approval process for nasal vaccines can be more challenging compared to traditional injectable vaccines. Regulators need to ensure the safety and efficacy of these vaccines, which can lead to longer development timelines and higher costs. To address this challenge, collaboration between vaccine developers and regulatory agencies is essential to streamline the approval process and establish clear guidelines for nasal vaccine development.

Key Market Trends

Technological Advancements

The global healthcare landscape is constantly evolving, with technological advancements at the forefront of innovation. One significant development is the growing interest in nasal vaccines, a novel approach to immunization that offers numerous advantages over traditional injection-based vaccines. These advancements have ignited a surge in the Global Nasal Vaccines Market, shaping the future of preventive medicine and public health.

Advancements in vaccine formulation have played a pivotal role in the growth of nasal vaccines. Researchers are developing new formulations that enhance vaccine stability, improve antigen delivery, and minimize side effects, thereby increasing their efficacy and safety. Adjuvants are substances added to vaccines to boost the body's immune response. Recent developments in adjuvant technology have led to the creation of nasal vaccines that can trigger stronger and more durable immune responses, improving their overall effectiveness.

Key Market Players

• Vaxart, Inc.
• FluGen Inc.
• Altimmune, Inc.
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Ennaid Therapeutics, LLC

Report Scope:

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit
• Recombinant and Conjugate Vaccines
• Others

Nasal Vaccines Market, By Application:

• Influenza
• COVID-19
• Others

Nasal Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Nasal Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant and Conjugate Vaccines, Others)
  • 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Nasal Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nasal Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Vaccine Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Nasal Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Vaccine Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Nasal Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Vaccine Type
      • 6.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nasal Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Nasal Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Nasal Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Nasal Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Vaccine Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Nasal Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Vaccine Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Nasal Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Nasal Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Nasal Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Nasal Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Nasal Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Nasal Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Application

9. South America Nasal Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Nasal Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Nasal Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Nasal Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Nasal Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Nasal Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Nasal Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Nasal Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Nasal Vaccines Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Vaxart, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. FluGen Inc.
• 14.3. Altimmune, Inc.
• 14.4. Sinovac Biotech Ltd.
• 14.5. Sanofi Pasteur SA
• 14.6. Pfizer Inc.
• 14.7. GlaxoSmithKline plc
• 14.8. Johnson & Johnson
• 14.9. Ennaid Therapeutics, LLC

15. Strategic Recommendations

16. About Us & Disclaimer